Johnson Johnson (NYSE: JNJ) has a lot going for it in the eyes of investors. The company's pharmaceutical sales are growing due to recently launched blockbuster drugs. Lately, its medical technology business is growing faster than pharmaceutical sales, thanks to a rush of seniors who need to replace their knees and hips.

Warren Buffett doesn't seem too thrilled with the stock, even though the company has a pair of business segments that keep moving in the right direction. Last year, Berkshire Hathaway, the holding company Buffett's managed since 1965, closed out a years-old Johnson Johnson position.

Is J still a good dividend stock to buy? Let's take a closer look at its recent performance to find out.

Continue reading

Source Fool.com